Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-05-2574
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Long-Term Molecular Responses to Imatinib in Patients With Chronic Myeloid Leukemia: Comparison Between Complete Cytogenetic Responders Treated in Early and in Late Chronic Phase

Haematologica
Hematology
2007English

Long-Term Impact of Molecular Response Fluctuations in Chronic Myeloid Leukaemia Patients Treated With Imatinib

British Journal of Haematology
Hematology
2017English

Effect of Tyrosine Kinase Inhibitor in Patients With Chronic Myeloid Leukemia (Cytogenetic, Molecular Response) in Mosul

Annals of the College of Medicine, Mosul
2018English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Prognostic Factors Associated With a Stable MR4.5 Achievement in Chronic Myeloid Leukemia Patients Treated With Imatinib

Oncotarget
Oncology
2017English

Secondary Myelodysplastic Syndrome in a Patient With Philadelphia-Positive Acute Lymphoblastic Leukemia After Achieving a Major Molecular Response With hyperCVAD Plus Imatinib Mesylate

Leukemia Research
Cancer ResearchOncologyHematology
2008English

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients With Chronic Myeloid Leukaemia

PLoS ONE
Multidisciplinary
2017English

Polycomb Genes Are Associated With Response to Imatinib in Chronic Myeloid Leukemia

Epigenomics
Cancer ResearchGenetics
2015English

Somatic Mutations Identified at Diagnosis by Exome Sequencing Can Predict Response to Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients

American Journal of Hematology
Hematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy